A CRITICAL REVIEW ON HYPOTHESIS, PATHOPHYSIOLOGY OF SCHIZOPHRENIA, AND ROLE OF VITAMINS IN ITS MANAGEMENT

  • Rosmi Jose Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Komarapalayam – 638 183, Tamil Nadu, India.
  • Venketeswaramurthy N Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Komarapalayam – 638 183, Tamil Nadu, India.
  • Sambath Kumar R Department of Pharmaceutics, J.K.K. Nattraja College of Pharmacy, Komarapalayam – 638 183, Tamil Nadu, India.

Abstract

This review describes about the literatures addressing the role of vitamin supplementation in schizophrenia. Evidence is suggesting that vitamin supplementation includes Vitamin A, Vitamin D, Vitamin E, Vitamin B complex, and Vitamin C may be important in treatment. In schizophrenia, patients may have increased level of homocysteine (Hcy), due to the polymorphism in methylenetetrahydrofolate reductase and hypofunction of N-methyl-D-aspartate receptors. The vitamins main effects are reduced the Hcy level and maintain dopamine and serotonin levels. Add-on treatment with high-dose B vitamins including B6, B9, and B12 and also Vitamin D can significantly reduce symptoms of schizophrenia more than standard treatments alone.

Keywords: Schizophrenia, Vitamin B, Vitamin D.

References

1. Schizophrenia. World Health Organization (WHO). 2017. Available from: http://www.who.int/topics/schizophrenia/en.
2. Jonathan EP. The clinical use of orthomolecules in the treatment of schizophrenia: Critical reflections and commentary. J Orthomol Psychiatry 2014;29:141-53.
3. Schultz SH, North SW, Shields CG. Schizophrenia: A review. Am Fam Physician 2007;75:1821-29.
4. Sridhar S, Ravi K, Raju M, Thomas L. A pilot study on utilization pattern of antipsychotic drugs in schizophrenic patients from southern India. WJPPS 2017;6:1301-8.
5. El-Hadidy MA, Abdeen HM, Abd El-Aziz SM. MTHFR gene polymorphism and age of onset of schizophrenia and bipolar disorder. Biomed Res Int 2014;2014:1-9.
6. Roy S, Awasthi H. Herbal medicines as neuroprotective agent: A mechanistic approach. Int J Pharm Pharm Sci 2017;9:1-7.
7. Gottesman II, Shields J. A polygenic theory of schizophrenia. Proc Natl Acad Sci USA 1967;58:199-205.
8. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005;10:40-68.
9. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007;20:687-702.
10. Raedler TJ, Knable MB, Weinberger DR. Schizophrenia as a developmental disorder of the cerebral cortex. Curr Opin Neurobiol 1998;8:157-61.
11. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999;122:593-624.
12. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: Systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188:510-8.
13. Seeman P, Kapur S. Schizophrenia: More dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000;97:7673-75.
14. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophr Res 2005;72:225-34.
15. Sansone RA, Sansone LA. Getting a knack for NAC: N-acetyl-cysteine. Innov Clin Neurosci 2011;8:10-4.
16. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008;33:2187-99.
17. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011;36:78-86.
18. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64:361-8.
19. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr., et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995;52:258-66.
20. Phukan P, Bawari M, Sengupta M. Promising neuroprotective plants from north-east India. Int J Pharm Pharm Sci 2015;7:28-39.
21. Ann BG. Chromosomal locations and modes of action of genes of the retinoid (Vitamin A) system support their involvement in the etiology of schizophrenia. Am J Med Genet 1995;60:335-48.
22. Lammer E. Preliminary observations on isotretretinoin induced ear malformations and pattern formation of the external ear. J Craniofac Genet Dev Biol 1991;11:292-5.
23. Hoffman C, Eichele G. Retinoids in development. In: Sporn MB, Roberts AB, Goodman DS, editors. The Retinoids: Biology, Chemistry and Medicine. 2nd ed. New York: Raven Press; 1994. p. 387441.
24. Morriss KG. Retinoic acid and craniofacial development. Bio Essays 1993;15:9-15.
25. Dingle JT, Barrett AJ, Weston PD, Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. Biochem J 1971;123:l-13.
26. Camisa C, Eisenstat B, Ragaz A, Weissmann G. The effects of retinoids on neutrophil functions in vitro. J Am Acad Dermatol 1982;6:620-9.
27. Meltzer HY. Treatment of the neuroloptic-nonresponsive schizophrenic patient. Schizophr Bull 1992;18:414-542.
28. Bao Y, Ibram G, Blaner WS, Quesenberry CP, Shend L, McKeagu LW, et al. Low maternal retinol as a risk factor for schizophrenia in adult offspring. Schizophr Res 2012;137:159-65.
29. McGrath J. Hypothesis: Is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schizophr Res 1999;40:173-77.
30. McGrath J, Saari K, Hakko H, Jokelainen J, Jones P, Järvelin MR, et al. Vitamin D supplementation during the first year of life and risk of schizophrenia: A Finnish birth cohort study. Schizophr Res 2004;67:237-45.
31. Stumpf WE, Sar M, Clark SA, DeLuca HF. Brain target sites for 1, 25-dihydroxyvitamin D3. Science 1982;215:1402-5.
32. Sutherland MK, Somerville MJ, Yoong LK, Bergeron C, Haussler MR, McLachlan DR. Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: Correlation with calbindin-28 k mRNA levels. Brain Res Mol Brain Res 1992;13:239-50.
33. Veenstra TD, Prufer K, Koenigsberger C, Brimijoin SW, Grande JP, Kumar R. 1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo. Brain Res 1998;804:193-205.
34. Prufer K, Veenstra TD, Jirikowski GF, Kumar R. Distribution of 1,25dihydroxyvitamin D3 receptor immune reactivity in the rat brain and spinal cord. J Chem Neuroanat 1999;16:135-45.
35. Musiol IM, Feldman D. 1,25-Dihydroxyvitamin D-3 expoinduction of nerve growth factor in L929 mouse fibroblasts: Effect of vitamin D receptor regulation and potency of vitamin D-3 analogs. Endocrinology 1997;138:12-8.
36. Eyles D, Brown J, Mackay-Sim A. McGrath J, Feron F. Vitamin D3 and brain development. Neuroscience 2003;118:641-53.
37. Eyles DW, Berne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 2013;34:47-64.
38. McGrath JJ, Burne TH, Féron F, Mackay-Sim A, Eyles DW. Developmental vitamin D deficiency and risk of schizophrenia: A 10- year update. Schizophr Bull 2010;36:1073-8.
39. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: Umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014;348:2035.
40. Schwartz PJ. Season of birth in schizophrenia: A maternal-fetal chronobiological hypothesis. Med Hypothesis 2011;76:785-93.
41. McGrath JJ, Eyles DW, Pedersen CB, Anderson C, Ko P, Burne TH, et al. Neonatal vitamin D status and risk of schizophrenia: A population based case-control study. Arch Gen Psychiatry 2010;67:889-94.
42. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
43. Valipour G, Saneei P, Esmaillzadeh A. Serum vitamin D levels in relation to schizophrenia: A systematic review and meta-analysis of observational studies. J Clin Endocrinol Metab 2014;99:3863-72.
44. Jan PA, Bostoen T, Theo GB. Low levels of vitamin D poorly responsive to daylight exposure in patients with therapy resistant schizophrenia. Nordic J Psychiatry 2015;10:262-6.
45. Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO, et al. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Interv Psychiatry 2015;9:397-405.
46. Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid Redox Signal 2011;15:2011-35.
47. Mahadik, SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: A review. Schizophr Res 1996;19:1-17.
48. Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996;19:19-26.
49. Perez-Neri I, Ramirez-Bermudez J, Montes S, Rios C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem Res 2006;31:1279-94.
50. Do K, Bovet P, Cuenod M. Schizophrenia: Glutathione deficit as a new vulnerability factor for disconnectivity syndrome. Schweiz Arch Psyciatr 2004;155:375-85.
51. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000;12:3721-8.
52. Wood SJ, Berger GE, Wellard RM, Proffitt TM, McConchie M, Berk M, et al. Medial temporal lobe glutathione concentration in first episode psychosis: A 1HMRS investigation. Neurobiol Dis 2009;33:354-7.
53. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: A 3T 1H-MRS study. PLoS One 2008;3:e1944.
54. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007;104:16621-26.
55. Nicolaus M, Hildegard S, Volker A, Erfurth A. Severe tardive dyskinesia in affective disorders: Treatment with vitamin E and C. Neuropsychobiology 2002;46:28-30.
56. Dorfman-Etrog P, Hermesh H, Prilipko L, Weizman A, Munitz H. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: An open label study. Eur Neuro Psycho Pharmacol 1999;9:475-77.
57. Hoffer LJ. Vitamin Therapy in Schizophrenia. Isr J Psychiatry Relat Sci 2008;45:3-10.
58. Brown HE, Roffman JL. Vitamin supplementation in the treatment of schizophrenia. CNS Drugs 2014;28:611-22.
59. Christopher W. Low B12 seen in aging, autism and schizophrenia. Live Sci 2016;10:1-2.
60. Shulman R. A survey of vitamin B12 deficiency in an elderly psychiatric population. Br J Psychiatry 1967;113:241-51.
61. Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry 2007;31:1289-96.
62. Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, et al. Meta-analyses of blood homocysteine level for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull 2014;40:1154-63.
63. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, et al. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism. Psychiatry Res 2010;175:47-53.
64. Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of folate vitamins in schizophrenia plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 2013;70:481-9.
65. Kemperman RF, Veurink M, van der Wal T, Knegtering H, Bruggeman R, Fokkema MR, et al. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 2006;74:75-85.
66. Muntjewerff JW, van der Put N, Eskes T, Ellenbroek B, Steegers E, Blom H, et al. Homocysteine metabolism and B-vitamins in schizophrenic patients: Low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Res 2003;121:1-9.
67. Emily D. Folate and Negative Symptoms in Schizophrenia. Available from: https://www.psychologytoday.com. [Last accessed on 2013 Jul 16].
68. Abou-Saleh MT, Coppen A. The biology of folate in depression: Implications for nutritional hypotheses of the psychoses. J Psychiatr Res 1986;20:91-101.
69. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;54:382-90.
70. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-5.
71. Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 2008;63:42-8.
72. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004;161:1705-8.
73. Vladimir L, Chanoch M, Alexander K, Cohen H, Matar M, Loewenthal U, et al. Vitamin B6 in the treatment of tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511-4.
74. Winslow LC, Shapiro H. Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch Intern Med 2002;162:1176-81.
75. Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: A double-blind, placebo-controlled study. J Clin Psychiatry 2002;63:54-8.
76. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 2006;60:265-9.
77. Spector RG, Lorenzo AV. Ascorbic acid homeostasis in the central nervous system. Am J Physiol 1973;225:757-63.
78. Saner A, Weiser H, Nornig D, De Prada M, Pletcher A. Cerebral monamine metabolism in guinea pigs with ascorbic acid deficiency. J Pharm Pharmacol 1975;27:896-902.
79. Deana R, Bharaj BS, Verjee ZM, Galzigna L. Changes relevant to catecholamine metabolism in liver and brain of ascorbic acid deficient guinea-pigs. Int J Vitam Nutr Res 1975;45:175-82.
80. Andersen JW, Shih JC. Necessity of ascorbic acid in the radioligand binding assay for (3H) 5-hydroxytryptamine. Neuropharmacology 1986;25:869-75.
81. Wyatt RJ, Vaugham T, Galanter M, Karlan J, Green R. Behavioral changes of chronic schizophrenic patients given L-5-hydroxytryptophan. Science 1972;177:1124-6.
82. Pauling L. On the orthomolecular environment of the mind: Orthomolecular theory. Am J Psychiatry 1974;131:1251-7.
83. Vanderkamp H. A biochemical abnonnality in schizophrenia involving ascorbic acid. Int J Neuropsychiatry 1966;2:204-6.
84. Herjanic M, Moss-Herjanic BL. Ascorbic acid test in psychiatric patients. J Schizophr 1967;1:257-60.
85. Thomas TN, Zemp JW. Inhibition of dopamine sensitive adenylate cyclase from rat brain striatal homogenates by ascorbic acid. J Neurochem 1977;28:663-5.
86. Tolbert LC, Thomas TN, Middaugh LD, Zemp JW. Effect of ascorbic acid on neurochemical, behavioral, and physiological symptoms mediated by catecholamines. Lqe Sci 1979;25:2189-95.
87. Heikkila RE, Manzino L, Cabbat FS, Hanly JG. Ascorbic acid and the binding of DA agonists to neostriatal membrane preparations. Neuropharmacology 1983;22:135-7.
88. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. J Psychopharmacol 2005;182:494-8.
Statistics
230 Views | 332 Downloads
Citations
How to Cite
Jose, R., V. N, and S. K. R. “A CRITICAL REVIEW ON HYPOTHESIS, PATHOPHYSIOLOGY OF SCHIZOPHRENIA, AND ROLE OF VITAMINS IN ITS MANAGEMENT”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 8, Aug. 2018, pp. 25-29, doi:10.22159/ajpcr.2018.v11i8.23259.
Section
Review Article(s)